Private Japanese moon probe snaps photo of lunar south pole ahead of June 5 landing
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Japan's private Resilience lunar lander has given us a nice shot of the moon just two weeks before its historic touchdown attempt.
On Thursday morning (May 22), the Tokyo-based company ispace, which built and operates Resilience, shared a photo on X that the probe took of the moon's south polar region.
"Resilience snapped this photo of the moon's south pole from lunar orbit, capturing the rough terrain of the many geological features of the lunar surface (which some say look like cheese from afar!). This image presents an optical illusion to some — although the image is filled with concave craters, from this orientation they may look like they are convex to the eye. What do you see: craters or bumps?" ispace wrote in the X post.
Resilience launched on Jan. 15 aboard a SpaceX Falcon 9 rocket that also carried another private moon lander: Firefly Aerospace's Blue Ghost.
Blue Ghost touched down on March 2, becoming just the second-ever commercial vehicle to soft-land successfully on the moon. (The first was Intuitive Machines' Odysseus spacecraft that touched down on the lunar surface in February of 2024.) Resilience — ispace's second-ever moon lander — took a longer, looping, energy-efficient route to Earth's nearest neighbor, finally arriving in lunar orbit on May 6.
The Japanese lander is scheduled to touch down on June 5 in Mare Frigoris ("Sea of Cold"), a volcanic plain in the moon's northern hemisphere. Success would be huge for ispace and for Japan; the nation has just one moon landing under its belt, that of the SLIM ("Smart Lander for Investigating Moon') spacecraft that landed in January 2024. (SLIM was operated by JAXA, Japan's national space agency.)
ispace came close to notching that milestone: Its first moon lander reached orbit successfully in March of 2023, but failed during its touchdown try a month later after getting confused by the rim of a crater.
Related stories:
— What's flying to the moon on ispace's Resilience lunar lander?
— Japan's Resilience moon lander aces lunar flyby ahead of historic touchdown try (photo)
— Japan's Resilience moon lander arrives in lunar orbit ahead of June 5 touchdown
Resilience is carrying five science and technology payloads to the moon, including a miniature rover named Tenacious.
The little wheeled robot, which was built by ispace's European subsidiary, will attempt to collect moon dirt under a contract that signed with NASA in 2020. Tenacious is also carrying some art on its front bumper — a piece called "Moonhouse" by Sweden's Mikael Genberg.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Sanofi to acquire Blueprint for up to $9.5B
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Looking to further amp up its immunology business, Sanofi has agreed to acquire Blueprint Medicines in a deal that could be worth as much as $9.5 billion. Blueprint's research revolves around an enzyme made by a gene called KIT. This 'tyrosine kinase' enzyme helps control cell development, division and survival, so if it mutates, it can spur the type of uncontrolled cell growth seen in cancer and some rare diseases. Blueprint already has one medicine approved by the Food and Drug Administration, Ayvakit, and is working on a handful of others, two of which are in human testing. The FDA first approved Ayvakit in early 2020 for a rare kind of hard-to-treat gastrointestinal tumor, and specifically for the small subset of adults who have these tumors and certain mutations. Since then, the agency cleared the medicine as a treatment for both the less and more aggressive forms of 'systemic mastocytosis,' an uncommon disorder where a kind of white blood cell known as a mast cell builds up in the bone marrow, digestive tract, skin and other organs. The accumulation can lead to severe inflammation and organ damage. Last year, Blueprint posted $479 million in net product revenue from Ayvakit. The company used to have another marketed cancer drug, Gavreto, which it was co-developing and commercializing with Roche. But Roche ultimately backed away from that alliance, leading Blueprint to sell away rights to Rigel Pharmaceuticals in early 2024. In a statement announcing the deal, Sanofi highlighted the recent trajectory in Ayvakit sales. They were up more than 60%, for example, between the first quarter of 2024 and the same three-month period this year. Blueprint recorded a $67 million net loss in 2024, compared to a more than half-a-billion-dollar net loss in each of the previous two years. The proposed acquisition 'represents a strategic step forward in our rare and immunology portfolios,' Sanofi CEO Paul Hudson said in the Monday statement. 'It enhances our pipeline and accelerates our transformation into the world's leading immunology company.' Hudson added that his company maintains a 'sizeable capacity for further acquisitions.' After being an active dealmaker over the past few years, the French pharmaceutical giant still had close to 8 billion euros in cash and cash equivalents at the end of March. Sanofi bought the diabetes drug developer Provention Bio for almost $3 billion in 2023 and the rare disease-focused Inhibrix for $2.2 billion in 2024. And just last month, it agreed to spend $470 million on Vigil Neuroscience, a Massachusetts-based biotechnology company touting an Alzheimer's disease drug that just finished an early-stage human study. Similar to its Vigil proposal, Sanofi is offering Blueprint investors a so-called contingent value right that could be worth up to $6 per Blueprint share, provided one of the biotech's experimental drugs, 'BLU-808,' hits certain development and regulatory goals. BLU-808 is in mid-stage testing as a possible treatment for chronic hives and an allergy-related condition that causes runny eyes and a congested nose. Blueprint also believes the drug could be useful in treating allergic asthma and 'mast cell activation syndrome.' Another Blueprint drug, elenestinib, is further along, having advanced to a late-stage study for the slower-moving form of systemic mastocytosis. Sanofi's upfront payment of $9.1 billion values Blueprint shares at $129 apiece, reflecting a premium of about 27% from the biotech's closing stock price on Friday. The transaction is expected to close sometime between July and the end of September, according to Sanofi. Andrew Berens, an analyst at the investment firm Leerink Partners, wrote in a note to clients how his team expected Blueprint to land on the 'strategic radar of large pharma' given Ayvakit is on the path to $1 billion or more in annual sales and the company recently raised its financial guidance for this year. However, the deal came sooner than anticipated, ahead of a key data readout for a rival drug from Cogent Biosciences. Cogent's bezuclastinib is also being evaluated as a treatment for systemic mastocytosis, with results set to arrive in the next couple months. Regardless of how strong or weak those results will be, Berens believes they'd serve as a tailwind for Blueprint 'by removing a key overhang and allowing a strategic acquirer to structure a deal based on assumptions about ... market dynamics.' As such, Cogent's data could have propped up Blueprint's share price, 'which may have been an impetus for Sanofi to do the deal now,' Berens posited. Even so, the analyst still sees Sanofi's bid as a positive for Blueprint and this field of research. Cogent shares were down by about 2% late Monday morning. Recommended Reading Blueprint wins key FDA approval for rare disease drug Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Clairity receives FDA OK for breast cancer risk prediction tool
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. The Food and Drug Administration has authorized the first artificial intelligence tool to predict patients' five-year breast cancer risk from a routine mammogram. Boston-based startup Clairity developed the tool, called Clairity Breast. The company plans to launch the risk assessment feature by the end of the year, according to a Monday announcement. 'We're doing something radically different than what I've done my whole career in the area of computer-aided detection and diagnosis of breast cancer,' Connie Lehman, founder of Clairity and a diagnostic radiologist at Mass General Brigham, said in an interview. AI has been used to detect breast cancer for decades; the first computer-aided detection system for breast cancer was approved in 1998, Lehman said. However, most of these tools are used to detect cancer, not predict future risk. 'What we're doing here is doing something humans can't do,' Lehman said. 'It's extracting subtle cues in the mammogram that the human eye can't see, the human brain can't process.' About 2.3 million new cases of breast cancer were diagnosed worldwide in 2022, according to the latest data from the World Health Organization. Current risk models factor in age and family history, but most people diagnosed have no family history. Lehman, who has focused most of her career on better ways to detect breast cancer early, expects the new approach will 'expand the net out to more women who truly are at high risk, and until now we haven't been able to identify.' Clairity Breast was developed using Hologic's 2D screening mammography systems. It would be used as part of a patient's routine mammogram. The company was careful to train its AI models on a diverse group of patients, Lehman said, as historically, breast cancer risk prediction models were built on data from predominantly white women. Clairity plans to launch the predictive tool starting with select centers and expanding access later this year, Lehman said. The company last year hired Jeffrey Luber as CEO to help lead the market launch. Luber is the former CEO of testing firms Binx Health and Exact Sciences. Clairity received a $1 million investment from the Breast Cancer Research Foundation in January. Recommended Reading Nvidia's David Niewolny on the future of AI in medical devices
Yahoo
an hour ago
- Yahoo
SpaceX will hit $15.5 billion in revenue this year, Elon Musk says
Elon Musk seems to think the sky isn't SpaceX's limit — and maybe not even its revenue ceiling. The CEO said on Tuesday that his company is on track to generate $15.5 billion in revenue in 2025, a leap from last year's estimated $11-13 billion. Musk posted SpaceX's revenue projections on X and added that, in 'perhaps an interesting milestone,' SpaceX's commercial revenue from space will exceed NASA's entire budget in 2026. The company will make about $1.1 billion alone through its work with NASA this year. SpaceX is one of the world's most valuable privately held companies, and its revenue is largely driven by two segments: its launch services and Starlink, its global satellite internet division. In February, Starlink claimed to have over five million customers worldwide; its base reportedly doubled from 2023 to 2024. Musk has said Starlink will go public once cash flow becomes more predictable — but hasn't specified when that might be. Meanwhile, SpaceX completed 134 launches in 2024 and is aiming for as many as 170 this year (it has already launched 62 times in 2025) — more than any other company or government space agency. Most of these are Falcon 9 missions, which have been used to deliver commercial satellites, government payloads, and NASA cargo. The rockets' reusability has been an advantage, and frequent launches have helped SpaceX secure a large share of the global market. But competitors such as Blue Origin and some international players are making progress, meaning the commercial launch market is getting more crowded. Much of the SpaceX's revenue is being plowed directly into the company's Starship program, which Musk sees as the key to interplanetary expansion — namely his plan to colonize Mars. Each Starship launch costs around estimated $100 million; Musk has said his goal is to lower that to around $10 million. But Starship has yet to demonstrate full mission success. A recent launch went father than ever before — but still ended with the rocket spinning out of control. For the latest news, Facebook, Twitter and Instagram. Sign in to access your portfolio
